{
    "clinical_study": {
        "@rank": "75657", 
        "acronym": "DIVA-REF", 
        "arm_group": [
            {
                "arm_group_label": "Ivabradine", 
                "arm_group_type": "Experimental", 
                "description": "Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months."
            }, 
            {
                "arm_group_label": "Digoxin", 
                "arm_group_type": "Experimental", 
                "description": "Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Study hypothesis: Comparing the effect of digoxin and ivabradine in chronic heart failure\n      patients with a left ventricular ejection  of 35% or lower and sinus rhythm with heart rate\n      70 beats per minute or higher, and who are taking maximal dose of a beta blocker if\n      tolerated."
        }, 
        "brief_title": "Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Selected patients have chronic heart failure with left ventricular systolic dysfunction and\n      sinus rhythm. They take optimal medical therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Inclusion Criteria:\n\n               -  Left ventricular ejection fraction of 35% or lower (Ischaemic or non-ischaemic\n                  etiology)\n\n               -  Sinus rhythm with heart rate of 70 beats per minute or higher\n\n               -  Symptomatic heart failure with functional capacity of New York Heart Association\n                  class II, III, IV\n\n          2. Exclusion Criteria:\n\n               -  Chronic renal failure with glomerular filtration rate <30 ml/min\n\n               -  Atrial fibrillation\n\n               -  Pace maker rhythm\n\n               -  Advanced stage chronic obstructive lung disease\n\n               -  Comorbidity with expected survival below 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046044", 
            "org_study_id": "KK&DU-Iva-Dig2014"
        }, 
        "intervention": [
            {
                "arm_group_label": "Digoxin", 
                "intervention_name": "Digoxin", 
                "intervention_type": "Drug", 
                "other_name": "Digoxin"
            }, 
            {
                "arm_group_label": "Ivabradine", 
                "intervention_name": "Ivabradine", 
                "intervention_type": "Drug", 
                "other_name": "Ivabradine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart failure", 
            "Digoxin", 
            "Ivabradine"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "kurtuluskarauzum@yahoo.com", 
                "last_name": "Kurtulus Karauzum, MD", 
                "phone": "90 555 726 87 90"
            }, 
            "facility": {
                "address": {
                    "city": "Kocaeli", 
                    "country": "Turkey"
                }, 
                "name": "Kocaeli University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm", 
        "other_outcome": {
            "measure": "Hospitalization for a cardiovascular reason", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 months"
        }, 
        "overall_contact": {
            "email": "kurtuluskarauzum@yahoo.com", 
            "last_name": "Kurtulus Karauzum, MD", 
            "phone": "90 555 726 87 90"
        }, 
        "overall_official": {
            "affiliation": "Kocaeli University", 
            "last_name": "Kurtulus Karauzum, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cardiac function (echocardiography): Systolic function (left ventricular ejection fraction) and diastolic function (Doppler E/A ratio, tissue Doppler e/e1 ratio, Doppler deceleration time of the E wave, left atrium volume index) Maximal oxygen consumption will be evaluated with cardiopulmonary exercise testing Changes in proBNP level (serum value) after treatment", 
            "measure": "Cardiac function and functional status and biochemical parameters", 
            "safety_issue": "No", 
            "time_frame": "After 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046044"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kocaeli University", 
            "investigator_full_name": "Kurtulus Karauzum", 
            "investigator_title": "Kurtulus Karauzum", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Death from cardiovascular reasons", 
                "measure": "Cardiovascular mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Death from any cause.", 
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Hospital admission for worsening heart failure", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Changes in heart rate and blood pressure.", 
                "measure": "Heart rate and blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "After 6 months"
            }
        ], 
        "source": "Kocaeli University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kocaeli University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}